Clinical Trials, Second Edition, offers those engaged in clinical trial design a valuable and practical guide. This book takes an integrated approach to incorporate biomedical science, laboratory data of human study, endpoint specification, legal and regulatory aspects and much more with the fundamentals of clinical trial design. It provides an overview of the design options along with the specific details of trial design and offers guidance on how to make appropriate choices. Full of numerous examples and now containing actual decisions from FDA reviewers to better inform trial design, the 2nd edition of Clinical Trials is a must-have resource for early and mid-career researchers and clinicians who design and conduct clinical trials.
Die Inhaltsangabe kann sich auf eine andere Ausgabe dieses Titels beziehen.
Dr. Tom Brody received his PhD from the University of California at Berkeley in 1980, and conducted postdoctoral research at University of Wisconsin-Madison and also at U.C. Berkeley. His 20 research publications concern the metabolism and pharmacology of folates, cloning an anti-cancer gene (XPE gene), and the structure of an antibody (natalizumab) used for treating multiple sclerosis. The author has 15 years of pharmaceutical industry experience, acquired at Schering-Plough, Cerus Corporation, and Elan Pharmaceuticals, and has contributed to FDA submissions for the indications of multiple sclerosis, melanoma, head and neck cancer, liver cancer, pancreatic cancer, and hepatitis C. At an earlier time, he wrote two editions of Clinical Trials, published by Elsevier, Inc. The author has 16 years of training and experience in the Code of Federal regulations, as it applies to pharmaceuticals and clinical trial design.
„Über diesen Titel“ kann sich auf eine andere Ausgabe dieses Titels beziehen.
Anbieter: medimops, Berlin, Deutschland
Zustand: very good. Gut/Very good: Buch bzw. Schutzumschlag mit wenigen Gebrauchsspuren an Einband, Schutzumschlag oder Seiten. / Describes a book or dust jacket that does show some signs of wear on either the binding, dust jacket or pages. Artikel-Nr. M00128042176-V
Anzahl: 1 verfügbar
Anbieter: Buchmarie, Darmstadt, Deutschland
Zustand: Good. Markierungen im Text. Namenseintrag. Buchschnitt leicht verschmutzt. Buchkanten angestoßen. Artikel-Nr. 3129723_69d
Anzahl: 1 verfügbar
Anbieter: La Casa de los Libros, Castellgali, B, Spanien
Zustand: Usado. Artikel-Nr. 9780128042175
Anzahl: 1 verfügbar
Anbieter: PBShop.store US, Wood Dale, IL, USA
HRD. Zustand: New. New Book. Shipped from UK. Established seller since 2000. Artikel-Nr. GB-9780128042175
Anbieter: PBShop.store UK, Fairford, GLOS, Vereinigtes Königreich
HRD. Zustand: New. New Book. Shipped from UK. Established seller since 2000. Artikel-Nr. GB-9780128042175
Anzahl: 1 verfügbar
Anbieter: Ria Christie Collections, Uxbridge, Vereinigtes Königreich
Zustand: New. In. Artikel-Nr. ria9780128042175_new
Anzahl: 1 verfügbar
Anbieter: Revaluation Books, Exeter, Vereinigtes Königreich
Hardcover. Zustand: Brand New. 2nd edition. 863 pages. 9.75x7.75x2.00 inches. In Stock. Artikel-Nr. __0128042176
Anzahl: 2 verfügbar
Anbieter: Speedyhen, Hertfordshire, Vereinigtes Königreich
Zustand: NEW. Artikel-Nr. NW9780128042175
Anzahl: 1 verfügbar
Anbieter: Kennys Bookstore, Olney, MD, USA
Zustand: New. . 2016. 2nd Edition. Hardcover. . . . . Books ship from the US and Ireland. Artikel-Nr. V9780128042175
Anzahl: 1 verfügbar
Anbieter: moluna, Greven, Deutschland
Zustand: New. Contains new and fully revised material on key topics such as biostatistics, biomarkers, orphan drugs, biosimilars, drug regulations in Europe, drug safety, regulatory approval and more Extensively covers the study schema and related fea. Artikel-Nr. 117662601
Anzahl: 1 verfügbar